The journal Circulation has now released an article on dabigatran (marketed as Pradaxa) discusses the indications and uses. Dabigatran will be available as an alternative to the usual anticoagulant, warfarin (coumadin), for prevention of stroke that can be an associated risk in patients with atrial fibrillation. It is not indicated for other coagulation problems at this time.
Many patients are enquiring about this alternative medication since measuring of blood tests (INR, Prothrombin time) will not be required.
However, patients need to consider ...Continue Reading →